CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 14, 2017--
Catabasis
Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage
biopharmaceutical company, today announced that the Company will present
results from the open-label extension of the MoveDMD trial following 24
and 36 weeks of edasalonexent treatment in boys with Duchenne Muscular
Dystrophy (DMD) at the 22nd International Congress of the
World Muscle Society. The late breaking abstract and results will be
available in the late breaking poster session starting at 10:30am CEST
on Wednesday, October 4, 2017. The International Congress of the World
Muscle Society is being held October 3 – 7, 2017, at the Palais du Grand
Large in Saint Malo, France.
About Edasalonexent
Edasalonexent (CAT-1004) is an
investigational oral small molecule that is being developed as a
potential disease-modifying therapy for all patients affected by DMD,
regardless of their underlying mutation. Edasalonexent inhibits NF-kB, a
protein that is activated in DMD and drives inflammation and fibrosis,
muscle degeneration and suppresses muscle regeneration. We are currently
conducting the MoveDMD trial, a three-part clinical trial investigating
the safety and efficacy of edasalonexent in boys enrolled at ages 4 – 7
affected with DMD (any confirmed mutation). The third part of the trial,
an open-label extension with edasalonexent, is ongoing. The FDA has
granted orphan drug, fast track and rare pediatric disease designations
and the European Commission has granted orphan medicinal product
designation to edasalonexent for the treatment of DMD. For a summary of
clinical results reported to-date, please visit www.catabasis.com.
About Catabasis
At Catabasis Pharmaceuticals, our mission is
to bring hope and life-changing therapies to patients and their
families. Our SMART (Safely Metabolized And Rationally Targeted) Linker
drug discovery platform enables us to engineer molecules that
simultaneously modulate multiple targets in a disease. We are applying
our SMART LinkerSM platform to build an internal pipeline of
product candidates for rare diseases and plan to pursue partnerships to
develop additional product candidates. For more information on the
Company's drug discovery platform and pipeline of drug candidates,
please visit www.catabasis.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170914005328/en/
Source: Catabasis Pharmaceuticals, Inc.
Investor and Media Contact
Catabasis
Pharmaceuticals, Inc.
Andrea Matthews, 617-349-1971
amatthews@catabasis.com
